FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
|Videos|November 2, 2020
The Forgotten Infectious Disease Issues During COVID-19
Author(s)Kevin Kunzmann
We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?
Advertisement
Last month, Contagion provided its typical coverage of the
Different from past years, though, was the team’s—and meeting’s—relegation to remote communication, due to the
Indeed, the greatest pandemic in modern history can generate enough research and discussion materials for the entirety of the IDWeek agenda, but the massive meeting nonetheless provided its standard bevy of topics: influenza and HIV; hepatitis and antimicrobial stewardship; hospital-acquired infection and vaccination.
Still, though, COVID-19 and its effect on the state of infectious disease loomed over all discussion. So, the Contagion team thought it’d be necessary to remember some forgotten issues in the field.
Enjoy this multi-expert answer to the IDWeek question, “Has COVID-19 taken attention away from any greater infectious disease issues?"
The video’s featured experts include:
- Matthew J. Ziegler, MD MSCE, Assistant Professor of Medicine, University of Pennsylvania
- Sarah Blevins, PharmD, HIV Clinical Pharmacist, University of Kentucky
- Joanne Langley, MD, Professor of Pediatrics, Canadian Center for Vaccinology, Dalhousie University
- Ravina Kullar, PharmD, MPH, Founder, duXsana
- Daniel J. Livorsi, MD, MSc, Assistant Professor, University of Iowa Carver College of Medicine
- Suchitra Rao, MBBS, MSCS, Associate Professor, University of Colorado School of Medicine
- Matthew Goetz, MD, Chief of Infectious Diseases, VA Greater Los Angeles Healthcare System, David Geffen School of Medicine, UCLA
Advertisement
Related to this article
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.
The FDA has approved Pfizer-BioNTech's 2026-2027 Comirnaty XFG formula, an updated COVID-19 vaccine targeting the XFG variant, for adults 65 and older and for individuals ages five through 64 with at least one high-risk underlying condition.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
Advertisement
Advertisement